- Home
- VRAX vs SGRX Comparison
VRAX vs SGRX Comparison
Compare VRAX & SGRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VRAX | SGRX |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United Kingdom | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5M | 1.7M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VRAX | SGRX |
|---|---|---|
| Price | $1.24 | $0.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 150.3K | ★ 7.5M |
| Earning Date | 11-20-2026 | 11-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.40 |
| 52 Week High | $13.19 | $1.92 |
Technical Indicators
Market Signals| Indicator | VRAX | SGRX |
|---|---|---|
| Relative Strength Index (RSI) | 21.48 | 28.31 |
| Support Level | $0.16 | N/A |
| Resistance Level | $3.01 | $1.89 |
| Average True Range (ATR) | 0.29 | 0.16 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 2.69 | 0.98 |
Price Performance
Historical ComparisonAbout VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.